Phase III Miss In Glioblastoma Burdens VBL's Ovarian Cancer Trial
Executive Summary
It's bad news for Israel's VBL as the company's lead gene-based biologic has failed in a critical Phase III trial in brain cancer – the pressure is on now for success with this drug candidate in ovarian cancer.
You may also be interested in...
BMS’s Opdivo Misses Again In Glioblastoma Phase III Trial
A second failure for BMS’s Opdivo in brain cancer leaves it with just one final chance in newly diagnosed disease, where the bar is lower.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.